# Diabetes Research Hub — Monitor Report
**Run date:** 2026-07-10
**Scan window:** since 2026-07-09 run
**Mode:** Automated review (no files modified)

---

## Executive Summary

All five core data files are fresh (generated today, 2026-07-10). Day-over-day change is
low: **3 new trials, 1 removed, 0 status changes, 0 new results posted** in the trial feed;
**30 new / 31 dropped** PubMed papers with **4 cross-domain** hits. No new FDA action or Phase 3
readout in the last 7 days that isn't already reflected in the tracked therapy list. Nothing
here is urgent. Two housekeeping items: the pipeline's own inputs (`agent_state`, `citation_validation`,
`evidence_network`, `gap_evidence`, dashboards) last refreshed 2026-07-09, and the monitor flags
804 result files >14 days old.

---

## File System Status

| File | Last modified | Status |
|------|---------------|--------|
| hub_monitor_report.md | 2026-07-10 02:17 | Fresh |
| clinical_trials_latest.json (852 trials) | 2026-07-10 02:07 | Fresh |
| pubmed_recent_latest.json (155 papers) | 2026-07-10 02:07 | Fresh |
| literature_gap_data.json | 2026-07-10 02:17 | Fresh |
| literature_gap_report.md | 2026-07-10 02:17 | Fresh |

Daily snapshots present and continuous through 2026-07-10 for both clinical trials and PubMed.
No missing expected files. Monitor review flag: **804 result files older than 14 days** — these are
mostly the historical snapshot archive and paper_library abstracts, expected to be static, but worth a
periodic prune.

**Trial feed composition (852 total):** T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 75 ·
T2D Novel Therapies (Ph 2–3) 147 · Diabetes Technology 235 · Recently Completed w/ Results 317.

---

## Clinical Trial Changes

### New since 2026-07-09 (3)
- **NCT07693036** — hUC-MSC-Exosomes for T2DM, Safety & Efficacy (Peking University First Hospital) — *Phase 1/2, RECRUITING*. Cell-derived exosome therapy for T2D; fits Tier-1 T1D/Cell-Therapy tracking by mechanism analogy.
- **NCT03263494** — CGM Intervention in Teens/Young Adults with T1D (Jaeb Center) — *Phase 3, COMPLETED, results posted 2026-07-09* (see below).
- **NCT07692321** — Co-designing Enhanced Models of Care for First Nations (University of Manitoba) — *NA, NOT_YET_RECRUITING*. Health-equity relevant.

### Removed (1)
- **NCT07357740** — insulin formulation comparison (was NOT_YET_RECRUITING). Dropped from the query window; likely a metadata/eligibility change rather than termination. [Guessing]

### Status changes: 0. New results posted in feed: 0 net new (the CGM trial above is the single fresh result).

### Key Phase-3 trials by tracked organization (current status)
- **Vertex — zimislecel / VX-880:** NCT06832410 and NCT04786262 both **RECRUITING** (Phase 3). VX-264 (NCT05791201) Ph1/2 active, not recruiting. No new PubMed papers on zimislecel this window (therapy hit count = 0).
- **Eli Lilly — baricitinib (T1D beta-cell preservation):** NCT07222332 and NCT07222137 both **RECRUITING** (Phase 3). Orforglipron and retatrutide programs multiple Phase 3, mostly ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING.
- **Novo Nordisk — insulin icodec:** NCT07076199 **RECRUITING** (Phase 3). CagriSema Phase 3 programs (NCT07282613, NCT06534411, others) active.

### Recently posted results worth a look
- **NCT04255433** (Lilly) — Tirzepatide vs Dulaglutide, Phase 3, results posted 2026-07-08.
- **NCT06340854** (Novo) — switching from daily basal to weekly insulin, Phase 3, results posted 2026-07-02.
- **NCT06010004** (Lilly) — Orforglipron long-term safety, Phase 3, results posted 2026-06-30.

---

## PubMed Highlights

Window: last 30 days, 155 unique papers across 16 alert domains.

### Cross-domain new papers (highest value — 4)
- **[42423034]** Olink proteomics of aqueous humor inflammatory biomarkers — *Diabetes Biomarker × Diabetes Complications*.
- **[42423124]** Diabetes risk in Hepatitis B patients, ML approach — *Diabetes AI/ML × Biomarker*.
- **[42423388]** CRP–triglyceride–glucose index as a novel T2D biomarker — *Diabetes AI/ML × Biomarker*.
- **[42426564]** SGLT2i and GLP-1 RA on ventricular arrhythmias — *T2D GLP-1 × Key Therapy: dapagliflozin*.

### Key-therapy mentions (30-day PubMed counts)
| Therapy | Total hits | Notable title |
|---------|-----------|---------------|
| dapagliflozin | 51 | high steady volume |
| orforglipron | 8 | Efficacy/safety in obesity + T2D [42363271]; hepatic safety [42338042] |
| retatrutide | 6 | learning/memory in STZ model [42385950] |
| teplizumab | 6 | Tzield delay of T1D [42332392]; expanded pediatric indication [42295172]; CGM response monitoring [42267680] |
| CagriSema | 4 | add-on to basal insulin [42251856] |
| icodec | 4 | — |
| baricitinib | 2 | VEXAS case report [42329752] |
| **zimislecel** | **0** | no new papers this window |

### Volume trend
Two-per-domain capture cap makes domain volume flat by design; therapy-level totals show
**dapagliflozin** dominating (51) and **teplizumab/orforglipron** both climbing on the back of
the recent label expansion and ACHIEVE readouts. **zimislecel at 0** is the notable quiet spot for a
Tier-1 cell-therapy asset — worth watching for the first post-approval clinical publications.

---

## Gap Analysis Summary

Top 5 under-researched intersections (gap score 100.0, all HIGH opportunity):

1. **Beta Cell Regen × Health Equity** — 0 joint pubs (expected ~1698)
2. **Insulin Resistance × Islet Transplant** — 1 (expected ~2223)
3. **Insulin Resistance × Closed Loop / AP** — 3 (expected ~6146)
4. **Islet Transplant × GWAS / Polygenic** — 0 (expected ~1148)
5. **Islet Transplant × Personalized Nutrition** — 0 (expected ~404)

**Alignment with Tier-1 contribution areas (RESEARCH_DOCTRINE):** Islet Transplant appears in
4 of the top 6 gaps and pairs directly with Tier-1 domains — GWAS/Polygenic (→ Multi-Omics
Integration, #1) and Health Equity (→ Epidemiological Analysis, #6). **Beta Cell Regen × Health Equity**
(rank 1) sits at the intersection of the cell-therapy pipeline and Tier-1 equity analysis. These are
the strongest "we have data + tools + a real gap" candidates. Caveat per doctrine: low counts for
Islet Transplant (248 total pubs) and Beta Cell Regen (1,458) partly reflect small field size and
possible terminology mismatch, not purely unexplored territory — verify before claiming a gap. [Likely]

---

## Breaking News (web, last 7 days)

Nothing requiring action beyond what the tracked data already reflects:

- **Orforglipron (Lilly), ACHIEVE-2/ACHIEVE-4** — Phase 3 readouts reported first-half 2026: superiority
  vs dapagliflozin on metformin background, plus CV/weight/glycemic benefit. Already tracked (8 PubMed hits;
  NCT06010004 long-term safety results posted 2026-06-30). Evidence level: **Phase 3 RCT (Level 1b)**.
- **Teplizumab (Tzield)** — pediatric label expansion to children ≥1 yr with stage 2 T1D. Confirmed by
  FDA notice and reflected in PubMed [42295172, 42332392]. Evidence level: **regulatory / Phase 3-supported**.
- **Retatrutide TRIUMPH / TRANSCEND-T2D** — 28% weight loss and ~2.0% HbA1c reduction; readouts from
  earlier in 2026, not new this week.
- **Generic dapagliflozin (Farxiga)** — first FDA generic approved 2026-04-07; not new this week.

No genuinely new (last-7-day) Phase 3 result or FDA approval identified.

---

## Recommended Actions

1. **Log the CGM T1D result** — NCT03263494 (Jaeb, Phase 3, results posted 2026-07-09) into
   `Diabetes_Research_Tracker.xlsx`; relevant to CGM Technology / Youth Diabetes tracking.
2. **Watch zimislecel publications** — Vertex Phase 3 trials both recruiting but 0 PubMed hits.
   First clinical papers will be high-value; keep the therapy alert on.
3. **Consider a Tier-1 gap deep-dive** on **Islet Transplant × GWAS/Polygenic** or **Beta Cell Regen ×
   Health Equity** — both are top-5 gaps aligned to Tier-1 (#1 Multi-Omics, #6 Epidemiology). Validate the
   gap is real (not terminology) before committing.
4. **Refresh derived analyses** — `agent_state.json`, `citation_validation.json`, `evidence_network.json`,
   `gap_evidence.json`, and dashboards last built 2026-07-09. If a daily rebuild is expected, re-run the
   pipeline (`python hub_monitor.py` and downstream scripts) to sync them to today's snapshots.
5. **Optional cleanup** — 804 result files flagged >14 days old (mostly archival snapshots). Prune or
   archive if disk/clarity matters; no action needed for correctness.

---

## Evidence & Method Notes (per Research Doctrine)

- Trial and PubMed counts are from ClinicalTrials.gov API v2 and PubMed E-utilities snapshots dated
  2026-07-10; diffs computed against 2026-07-09 snapshots.
- Gap scores are relative measures (PubMed keyword matching, not exact MeSH); treat as hypotheses, not
  conclusions. Low-count domains flagged for terminology-mismatch risk.
- Web items rated by evidence level where a claim is made; no new claims added to the corpus in this
  review run.
- No existing files were modified.

*Generated by diabetes-hub-monitor scheduled task — 2026-07-10*
